- Home
- CRGX vs FVR Comparison
CRGX vs FVR Comparison
Compare CRGX & FVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- FVR
- Stock Information
- Founded
- CRGX 2021
- FVR 2016
- Country
- CRGX United States
- FVR United States
- Employees
- CRGX N/A
- FVR N/A
- Industry
- CRGX
- FVR
- Sector
- CRGX
- FVR
- Exchange
- CRGX Nasdaq
- FVR NYSE
- Market Cap
- CRGX 190.0M
- FVR 227.7M
- IPO Year
- CRGX 2023
- FVR 2024
- Fundamental
- Price
- CRGX $4.20
- FVR $12.14
- Analyst Decision
- CRGX Hold
- FVR Hold
- Analyst Count
- CRGX 7
- FVR 5
- Target Price
- CRGX $4.67
- FVR $16.80
- AVG Volume (30 Days)
- CRGX 591.0K
- FVR 349.6K
- Earning Date
- CRGX 08-11-2025
- FVR 08-15-2025
- Dividend Yield
- CRGX N/A
- FVR 7.17%
- EPS Growth
- CRGX N/A
- FVR N/A
- EPS
- CRGX N/A
- FVR N/A
- Revenue
- CRGX N/A
- FVR $60,901,000.00
- Revenue This Year
- CRGX $57.81
- FVR $18.42
- Revenue Next Year
- CRGX N/A
- FVR $6.26
- P/E Ratio
- CRGX N/A
- FVR N/A
- Revenue Growth
- CRGX N/A
- FVR 15.85
- 52 Week Low
- CRGX $3.00
- FVR $10.61
- 52 Week High
- CRGX $25.45
- FVR $19.76
- Technical
- Relative Strength Index (RSI)
- CRGX 44.13
- FVR N/A
- Support Level
- CRGX $4.07
- FVR N/A
- Resistance Level
- CRGX $4.31
- FVR N/A
- Average True Range (ATR)
- CRGX 0.17
- FVR 0.00
- MACD
- CRGX -0.03
- FVR 0.00
- Stochastic Oscillator
- CRGX 18.62
- FVR 0.00
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About FVR FRONTVIEW REIT INC
FrontView REIT Inc is an internally managed net-lease REIT that is experienced in acquiring, owning, and managing out parcel properties that are net-leased to a diversified group of tenants. The tenants of the company include service-oriented businesses, such as restaurants, cellular stores, financial institutions, automotive stores and dealers, medical and dental providers, pharmacies, convenience and gas stores, car washes, home improvement stores, grocery stores, professional services as well as general retail tenants.